Literature DB >> 17889571

Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture: cellular and molecular characterization.

Luisa Ronzoni1, Paola Bonara, Daniela Rusconi, Cecilia Frugoni, Ilaria Libani, Maria Domenica Cappellini.   

Abstract

In vitro models of human erythropoiesis are useful in studying the mechanisms of erythroid differentiation from BFU-E to mature erythrocytes both in normal and pathological conditions. Most of the available in vitro liquid cultures are from cell lines or are limited by the production of few erythroid cells mixed with myeloid cells. Here we describe an erythroid liquid culture system starting from CD34(+)-enriched cells obtained from peripheral blood. CD34(+) cells were cultured for 21 days in different conditions. Precisely stem cell factor (SCF, 20 ng/mL) and IL-3 (10 ng/mL) were added at starting point plus Epo (3 U/mL) at day 0 or 7 of culture with or without cyclosporine A (Cy; 1 mg/mL). In all the conditions, the highest recovery was obtained at day 14 of culture. Epo and Cy added at day 0 produced the highest cell expansion (170-fold mean amplification of the initial cell input by day 14) and recovery of erythroid cell. Sixty seven percent of the cells were GP(+) at day 7 and 97% by day 14 respectively. Most of the cells were proerythroblasts at day 7 and mature erythroblasts at day 14 (>90% were benzidine(pos)). The presence of Cy favoured erythroid differentiation and maturation and reduced the percentage of non-erythroid CD45(+) cells (2% with Cy versus 5% without Cy). Cells cultured with Epo and Cy reproduced erythropoiesis also at the molecular level. The results suggest that in 14 days different steps of human erythropoiesis from peripheral CD34(+) cells could be reproduced, with high recovery of highly purified erythroid cells. The high number and purity of erythroid cells produced from a small amount of peripheral blood make this method useful for studying either normal or pathological erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889571     DOI: 10.1016/j.bcmd.2007.07.006

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  10 in total

1.  Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II.

Authors:  Klaus Schwarz; Achille Iolascon; Fatima Verissimo; Nikolaus S Trede; Wyatt Horsley; Wen Chen; Barry H Paw; Karl-Peter Hopfner; Karlheinz Holzmann; Roberta Russo; Maria Rosaria Esposito; Daniela Spano; Luigia De Falco; Katja Heinrich; Brigitte Joggerst; Markus T Rojewski; Silverio Perrotta; Jonas Denecke; Ulrich Pannicke; Jean Delaunay; Rainer Pepperkok; Hermann Heimpel
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

Review 2.  Ex-vivo expansion of red blood cells: how real for transfusion in humans?

Authors:  Anna Rita Migliaccio; Elena Masselli; Lilian Varricchio; Carolyn Whitsett
Journal:  Blood Rev       Date:  2011-12-15       Impact factor: 8.250

3.  EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.

Authors:  Silverio Perrotta; Valeria Cucciolla; Marcella Ferraro; Luisa Ronzoni; Annunziata Tramontano; Francesca Rossi; Anna Chiara Scudieri; Adriana Borriello; Domenico Roberti; Bruno Nobili; Maria Domenica Cappellini; Adriana Oliva; Giovanni Amendola; Anna Rita Migliaccio; Patrizia Mancuso; Ines Martin-Padura; Francesco Bertolini; Donghoon Yoon; Josef T Prchal; Fulvio Della Ragione
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

4.  Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in β-thalassemic erythropoiesis.

Authors:  Lucia De Franceschi; Mariarita Bertoldi; Luigia De Falco; Sara Santos Franco; Luisa Ronzoni; Franco Turrini; Alessandra Colancecco; Clara Camaschella; Maria Domenica Cappellini; Achille Iolascon
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

5.  A highly conserved SOX6 double binding site mediates SOX6 gene downregulation in erythroid cells.

Authors:  Claudio Cantu'; Vito Grande; Ilaria Alborelli; Letizia Cassinelli; Ileana Cantu'; Maria Teresa Colzani; Rossella Ierardi; Luisa Ronzoni; Maria Domenica Cappellini; Giuliana Ferrari; Sergio Ottolenghi; Antonella Ronchi
Journal:  Nucleic Acids Res       Date:  2010-09-17       Impact factor: 16.971

6.  Congenital dyserythropoietic anemia type II: molecular analysis and expression of the SEC23B gene.

Authors:  Francesca Punzo; Aida M Bertoli-Avella; Saverio Scianguetta; Fulvio Della Ragione; Maddalena Casale; Luisa Ronzoni; Maria D Cappellini; Gianluca Forni; Ben A Oostra; Silverio Perrotta
Journal:  Orphanet J Rare Dis       Date:  2011-12-30       Impact factor: 4.123

7.  Identification of circulating CD31+CD45+ cell populations with the potential to differentiate into erythroid cells.

Authors:  Maria Chiara G Monaco; Dragan Maric; Ombretta Salvucci; Cristina Antonetti Lamorgese Passeri; Patrizia Accorsi; Eugene O Major; Anna Concetta Berardi
Journal:  Stem Cell Res Ther       Date:  2021-04-13       Impact factor: 6.832

8.  Erythroid Differentiation and Heme Biosynthesis Are Dependent on a Shift in the Balance of Mitochondrial Fusion and Fission Dynamics.

Authors:  Alvaro M Gonzalez-Ibanez; Lina M Ruiz; Erik Jensen; Cesar A Echeverria; Valentina Romero; Linsey Stiles; Orian S Shirihai; Alvaro A Elorza
Journal:  Front Cell Dev Biol       Date:  2020-11-23

9.  Promotion of Erythropoietic Differentiation in Hematopoietic Stem Cells by SOCS3 Knock-Down.

Authors:  Yu-xiao Liu; Xing Dong; Feng Gong; Ning Su; Su-bo Li; Hai-tao Zhang; Jia-ling Liu; Jing-hui Xue; Shou-ping Ji; Zhi-wen Zhang
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

Review 10.  Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.

Authors:  J-F Stoltz; N de Isla; Y P Li; D Bensoussan; L Zhang; C Huselstein; Y Chen; V Decot; J Magdalou; N Li; L Reppel; Y He
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.